Literature DB >> 33937942

Therapeutic effects and limitations of chemoradiotherapy in advanced lower rectal cancer focusing on T4b.

Kosuke Ozaki1, Kazushige Kawai2, Hiroaki Nozawa2, Kazuhito Sasaki2, Koji Murono2, Shigenobu Emoto2, Yuuki Iida2, Hiroaki Ishii2, Yuichiro Yokoyama2, Hiroyuki Anzai2, Hirofumi Sonoda2, Kenichi Sugihara3, Soichiro Ishihara2.   

Abstract

PURPOSE: This study aimed to elucidate the benefits and limitations of preoperative chemoradiotherapy (CRT) in rectal cancer treatment, specifically in T4b rectal cancer.
METHODS: This retrospective cohort study reviewed 1014 consecutive patients with clinical T3/4a/T4b adenocarcinomas of the lower rectum, who underwent total mesorectal excision at the Department of Surgical Oncology of the University of Tokyo Hospital and 22 referral institutions affiliated with the Japanese Study Group for Postoperative Follow-up of Colorectal Cancer. Patients were divided into two cohorts: cohort 1 comprised 298 consecutive patients who underwent CRT followed by radical surgery and cohort 2 comprised 716 consecutive patients who underwent curative surgery without preoperative therapy. We assessed the prognostic differences between the two cohorts, focusing particularly on T stages.
RESULTS: In T3/4a patients, cohort 1 showed a significantly lower local recurrence rate than cohort 2 (4.8% vs. 9.4%, p=0.024), but not in T4b patients (23.5% vs. 16.0%, p=0.383). In contrast, no significant differences in survival were observed between T3/4a and T4b patients. T4b classification was found to be an independent predictive factor of local recurrence in cohort 1, but not in cohort 2.
CONCLUSION: In T4b rectal cancer, preoperative CRT demonstrated a limited benefit for local control and survival. In cases of suspected T4b rectal tumors, additional therapies such as induction chemotherapy to conventional CRT may contribute to better outcomes.

Entities:  

Keywords:  Cancer; Chemoradiotherapy; Rectal; T4b

Year:  2021        PMID: 33937942     DOI: 10.1007/s00384-021-03936-4

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  26 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients.

Authors:  Thomas Lehnert; Mascha Methner; Andreas Pollok; Anja Schaible; Ulf Hinz; Christian Herfarth
Journal:  Ann Surg       Date:  2002-02       Impact factor: 12.969

Review 3.  Surgery for Locally Advanced T4 Rectal Cancer: Strategies and Techniques.

Authors:  Ramzi M Helewa; Jason Park
Journal:  Clin Colon Rectal Surg       Date:  2016-06

4.  En bloc resection of colon cancer adherent to other organs.

Authors:  J A Hunter; J A Ryan; P Schultz
Journal:  Am J Surg       Date:  1987-07       Impact factor: 2.565

5.  Differential effect of concurrent chemotherapy regimen on clinical outcomes of preoperative chemoradiotherapy for locally advanced rectal cancer.

Authors:  Eunji Kim; Kyubo Kim; Do Hoon Oh; Sae-Won Han; Tae-You Kim; Seung-Yong Jung; Kyu Joo Park; Gyeong Hoon Kang; Eui Kyu Chie
Journal:  J BUON       Date:  2019 Mar-Apr       Impact factor: 2.533

6.  Multivisceral resections in colorectal cancer.

Authors:  F P Gall; J Tonak; A Altendorf
Journal:  Dis Colon Rectum       Date:  1987-05       Impact factor: 4.585

7.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Glynne-Jones; L Wyrwicz; E Tiret; G Brown; C Rödel; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

8.  The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Authors:  Stephen B Edge; Carolyn C Compton
Journal:  Ann Surg Oncol       Date:  2010-06       Impact factor: 5.344

9.  Prognostic factors and patterns of failure after surgery for T4 rectal cancer in the beyond total mesorectal excision era.

Authors:  O Peacock; P S Waters; M Bressel; A C Lynch; C Wakeman; T Eglinton; C E Koh; P J Lee; K K Austin; S K Warrier; M J Solomon; F A Frizelle; A G Heriot
Journal:  Br J Surg       Date:  2019-07-24       Impact factor: 6.939

Review 10.  Multivisceral resection for T4 or recurrent colorectal cancer.

Authors:  J O Larkin; P R O'Connell
Journal:  Dig Dis       Date:  2012-11-23       Impact factor: 2.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.